1.
J Pediatr Hematol Oncol
; 39(2): 126-132, 2017 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27509379
RESUMO
Hydroxyurea, blood transfusions, and hematopoietic stem cell transplantation represent the 3 disease-modifying therapies in children with sickle cell disease (SCD). Blood transfusions play an increasingly important role in both prevention and management of SCD complications in this age group. This review will focus on the indications of blood transfusion in children with SCD and modalities of its administration. It will also highlight the complications of this life-saving therapy and ways of optimizing transfusion to minimize its associated risks.